



USAMRDC Good News Story



U.S. Army Medical Research and Development Command

USAMRIID, Key Partners Deliver Hope in Global Fight Against Ebola

- An investigational Ebola vaccine known as V920, developed by Merck Research Laboratories and tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), has reached a significant regulatory milestone.
- On September 17, Merck announced the U.S. Food and Drug Administration granted priority review for the product, which was evaluated by USAMRIID in four pivotal studies to evaluate its protective efficacy in nonhuman primates.
- USAMRIID also examined durability of immunogenicity and protection post-vaccination; and further conducted other studies to better understand the differences in immune response that potentially correlate with protection. This information could be instrumental in predicting levels of protection in populations at risk for Ebola virus infection.
- These studies were conducted with funding provided by the Defense Threat Reduction Agency-Joint Science and Technology Office and by the Joint Program Executive Office for Chemical and Biological Defense-Medical Countermeasure Systems.



Vials of the investigational Ebola vaccine V920 (Courtesy Merck)

OUTCOME: The work performed by USAMRIID demonstrates the impact of USAMRDC's overall research efforts on global and Warfighter health, and exemplifies how government agencies and commercial partners can work together to advance medical countermeasure development.